At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 52 enrolled
Drug / intervention
Experimental BHVI2 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A One-month, Randomized, Single Centre, Double-masked, Comparative Study to Evaluate the Short-term Ocular Effects of Experimental BHVI2 and 0.02% Atropine Eye Drops Either Alone or in Combination
In Brief
A Phase 1 clinical trial evaluating Experimental BHVI2, Atropine sulfate 0.02% eye drops, and 1 other intervention for Myopia. Completed, enrolled 52 participants across 1 site.
Detailed Summary
To assess the one-month ocular effects of nightly application of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination, in children aged between 6 to 13 years old with myopia and randomized to use of experimental BHVI2 eye drops, 0.02% atropine eye drops, experimental BHVI2 plus 0.02% atropine eye drops.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia
CountriesVietnam
CollaboratorsBrien Holden Vision
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2018
Primary CompletionFeb 2019
Study CompletionJun 2019
TodayJul 2026
First PostedOct 1, 2018
Enrollment StartOct 1, 2018
Primary CompletionFeb 2, 2019
Study CompletionJun 30, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.8 years ago
Interventions
Experimental BHVI2drug
Experimental BHVI2 eye drops
Atropine sulfate 0.02% eye dropsdrug
Atropine eye drops
Combination eye dropscombination
Combination eye drops with experimental BHVI2 plus 0.02% atropine